CAMG
AKTX

CWA Asset Management Group’s Akari Therapeutics AKTX Stock Holding History

CWA Asset Management Group’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,375
Closed -$15.9K – 683
2025
Q4 		$15.9K Buy
+1,375
New +$31.9K ﹤0.01% 640

Other funds holding AKTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

CWA Asset Management Group's AKTX Position: Q1 2026 in Review

CWA Asset Management Group sold out of Akari Therapeutics (AKTX) in Q1 2026, closing a stake of 1,375 shares — an estimated $15.9K sold.

CWA Asset Management Group first reported a position in AKTX in Q4 2025 and held it in 1 quarter. The position peaked at $15.9K in Q4 2025. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.

  • CWA Asset Management Group reported no remaining Akari Therapeutics position as of Q1 2026 after selling out during the quarter.
  • CWA Asset Management Group sold 1,375 Akari Therapeutics shares in Q1 2026, an estimated $15.9K.
  • CWA Asset Management Group first reported a position in Akari Therapeutics in Q4 2025 and held it in 1 quarter.
  • CWA Asset Management Group's Akari Therapeutics position peaked at $15.9K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.

Based on CWA Asset Management Group's 13F filing for Q1 2026, filed 20 Apr 2026.